Five different mechanisms have been proposed whereby antidepressant treatment might lead to suicide: first by simply ameliorating depressions more rapidly; second by an action intrinsic to the specific antidepressant effects; third by toxicity in overdose; fourth by side-effects of specific antidepressants; and finally by virtue of treatment inefficacy. Evidence from randomized control trials (RCT), controlled case studies and epidemiological studies on this question is reviewed and it is concluded that antidepressants can be implicated in some cases of suicide during treatment. Modifications of clinical trial methods and pharmacogenetic studies would yield a richer data set to explore this issue further.
Ayd F Jr (1996) Lexicon for psychiatry, neurology and neuroscience, p. 268-268. Williams & Wilkins, Baltimore
2.
Beasley C (1991) Fluoxetine and suicide. BMJ303: 1200-1200
3.
Beasley C M, Dornseif B E, Bosomworth JC, Sayler M E, Rampey A H, Heiligenstein J H, Thompson V L, Murphy D J, Masica DN (1991) Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ303: 685-692
4.
Blacker R, Clare A (1987) Depressive disorder in primary care. Br J Psychiatry150: 737-751
5.
Cassidy S L, Henry JA (1987) Fatal toxicity of antidepressant drugs in overdose. BMJ295: 1021-1024
6.
Creaney W, Murray I, Healy D (1991) Antidepressant induced suicidal ideation. Hum Psychopharmacol6: 329-332
7.
Damluji N F, Ferguson J M (1988) Paradoxical worsening of depressive symptoms caused by antidepressants. J Clin Psychopharmacol8: 347-349
8.
Davies D L, Shepherd M (1955) Reserpine in the treatment of anxious and depressed patients. Lancet117-120
9.
Edwards G (1992) Antidepressants and murder. Psychiatr Bull16: 537-539
10.
Fawcett J, Scheftner WA, Fogg L, Clark D C, Young MA, Hedeker D, Gibbons R (1990) Time-related predictors of suicide in major affective disorders. Am J Psychiatry147: 1189-1194
11.
Fawcett J (1992) Suicide risk factors in depressive disorders and in panic disorder. J Clin Psychiatry53: 9-13
12.
Girard M (1987) Conclusiveness of rechallenge in the interpretation of adverse drug reactions. Br J Clin Pharmacology23: 73-79
13.
Guze S, Robins E (1970) Suicide and primary affective disorder: a study of 95 cases. Br J Psychiatry117: 437-438
14.
Hagnell O, Lanke J, Rorsman B (1981) Suicide rates in the Lundby study: mental illness as a risk factor for suicide. Neuropsychobiology7: 248-253
15.
Healy D (1994) The fluoxetine and suicide controversy. CNS Drugs1: 223-231
16.
Healy D (1997) The antidepressant era. Harvard University Press, Cambridge, MA
17.
Healy D (1998) Meta-analysis of trials comparing antidepressants with active placebos. Br J Psychiatry172: 232-234
18.
Healy D, Farquhar G N (1998) Responses to droperidol in healthy volunteers. Hum Psychopharmacol13: 113-120
19.
Healy D, Savage M (1998) Reserpine exhumed. Br J Psychiatry172: 376-378
20.
Henry JA (1992) The safety of antidepressants. Br J Psychiatry160: 439-441
21.
Hill A B (1966) Reflections on the controlled trial. Ann Rheum Dis25: 107-113
22.
Inskip H M, Harris EC, Barraclough B (1998) Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. Br J Psychiatry172: 35-37
23.
Isacsson G, Holmgren P, Wasserman D, Bergman U (1994) Use of antidepressants among people committing suicide in Sweden. BMJ308: 506-509
24.
Jick H, Ulcickas M, Dean A (1992) Comparison of frequencies of suicidal tendencies among patients receiving fluoxetine, lofepramine, mianserin or trazodone. Pharmacotherapy12: 451-454
25.
Jick S, Dean A D, Jick H (1995) Antidepressants and suicide. BMJ310: 215-218
26.
Joyce P R, Mulder RT, Cloninger C R (1994) Temperament predicts clomipramine and desipramine responses in major depression. J Affective Disorders30: 35-46
27.
Karch F E, Lasagna L (1977) Towards the operational identification of adverse drug reactions. Clin Pharmacol Therapeut21: 247-253
28.
Kazdin A (1982) Single-case research designs. Oxford University Press, New York
29.
Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen H U, Kendler K S (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Co-morbidity study. Arch Gen Psychiatry51: 8-19
30.
Kielholz P, Battegay R (1958) The treatment of depressive states: with special reference to Tofranil, a new antidepressive. Schweizerische Medizinische Wochenschrift88: 763-767
31.
Kielholz P (1971) Diagnose und Therapie der Depressionen fur Praktiker. JF Lehmanns, Munich
32.
King R A, Riddle M A, Chappell P B, Hardin M T, Anderson G M, Lombroso P, Scahill L (1991) Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry30: 171-176
33.
Knorring von L, Bingefors K (1998) Resistant depression: the need for better antidepressants. In Briley M, Montgomery S (eds), Antidepressant therapy at the dawn of the third millennium, pp. 319-332. Martin Dunitz, London
34.
Leber P (1998) Managing uncertainty. In Healy D (ed.), The psychopharmacologists, Vol. 2. Chapman & Hall, London
35.
Lingjaerde O, Ahlfors U G, Bech P, Dencker S J, Elgen K (1987) The UKUside-effect rating scale. Acta Psychiatr Scand76 (Suppl.): 334-334
36.
Lipinski J F, Mallya G, Zimmerman P et al. (1989) Fluoxetine induced akathisia: clinical and theoretical implications. J Clin Psychiatry50: 339-342
37.
Lopez-Ibor JJ, Guelfi J, Pletan Y, Tournox A, Prost JF (1996) Milnacipram and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol11 (Suppl. 4): 41-46
38.
Moller H-J (1992) Attempted suicide: efficacy of different aftercare strategies. Int Clin Psychopharmacol6 (Suppl. 6): 58-69
39.
Montgomery SA, Montgomery DB (1982) Pharmacological prevention of suicidal behaviour. J Affect Disord4: 291-298
40.
Montgomery SA, Dunner D L, Dunbar G C (1995) Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol5: 5-13
41.
Nakielny J (1994) The fluoxetine and suicide controversy. A review of the evidence. CNS Drugs2: 252-253
42.
Pare C M B, Rees W L, Sainsbury M J (1962) Differentiation of two genetically specific types of depression by the responses to anti-depressants. Lancet 1340-1343
43.
Patterson WM (1993) Fluoxetine-induced sexual dysfunction. J Clin Psychiatry54: 71-71
44.
Pinder R (1988) The risks and benefits of antidepressant drugs. Human Psychopharmacology3: 73-86
45.
Plewes J M, Koke S C, Sayler M E (1997) Adverse events and treatment discontinuations in fluuoxetine clinical trials: an updated meta-analysis. Eur Neuropsychopharmacol7: S169-S169
46.
Rothschild A J, Locke CA (1991) Re-exposure to fluuoxetine after serious suicide attempts by 3 patients: the role of akathisia. J Clin Psychiatry52: 491-493
47.
Rouillon F, Phillips R, Serrurier D, Ansart E, Gerard M J (1989) Rechutes de depression unipolaire et efficacite de la maprotiline. L'Encephale15: 527-534
48.
Rutz W, von Knorring L, Pihlgren H, Rihmer Z, Walinder J (1995) An educational project on depression and its consequences: is frequency of major depression among Swedish men underrated resulting in high suicidality?Primary Care Psychiatry1: 59-63
49.
Sachdev P (1995) Akathisia and restless legs. Cambridge University Press, Cambridge
50.
Staehelin J (1955) Ûber DepressionszustÌnde. Schweiz Med Wochenschrift85: 1205-1205
51.
Stark P, Hardison C D (1985) A review of multicenter controlled studies of fluuoxetine versus imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry46: 53-58
52.
Stecklow S, Johannes L (1997) Questions arise on new drug testing. Drug makers relied on clinical researchers who now await trial. Wall Street Journal 15 August
53.
Stephens M (1983) Deliberate drug rechallenge. HumToxicol2: 573-577
54.
Teicher M H, Glod C, Cole J O (1990) Emergence of intense suicidal preoccupation during fluuoxetine treatment. Am J Psychiatry147: 207-210
55.
Teicher M H, Glod C, Cole J O (1991) DrTeicher and associates reply. Am J Psychiatry147: 1692-1693
56.
Teicher M H, Glod C, Cole J O (1990c) Dr Teicher and associates reply. Am J Psychiatry148: 1260-1262
57.
Tollefson G D, Greist J H, Jefferson J W, Heiligenstein J H, Sayler M E, Tollefson S L, Koback K (1994) Is baseline agitation a relative contra-indication for a SSRI: a comparative trial of fluuoxetine versus imipramine. J Clin Psychopharmacol14: 385-391
58.
Van der Sande R, Van Rooijen L, Buskens E, Allart E, Hawton K, Van der Graaf Y, Van Engeland H (1997) Intensive in-patient and community intervention versus routine care after attempted suicide. Br J Psychiatry171: 35-41
59.
Wheatley D, van Moffaert M, Timmerman L et al. (1998) Mirtazapine: effciency and tolerability in comparison with fluuoxetine in patients with major depression. J Clin Psychiatry (in press)
60.
WHO (1994) International monitoring of adverse reactions to drugs. Adverse reaction terminology.WHO, Geneva
61.
Wirshing WC, Van Putten T, Rosenberg J, Marder S, Ames D, Hicks-Gray T (1992) Fluoxetine, akathisia and suicidality: is there a causal connection?Arch Gen Psychiatry49: 580-581
